Elisa Giovannetti1, Qiuyan Wang, Amir Avan, Niccola Funel, Tonny Lagerweij, Jih-Hsiang Lee, Viola Caretti, Arjan van der Velde, Ugo Boggi, Yisong Wang, Enrico Vasile, Godefridus J Peters, Thomas Wurdinger, Giuseppe Giaccone. 1. Affiliations of authors: Department of Medical Oncology (EG, AA, GJP) and Department of Neurosurgery (TL, VC, TW), VU University Medical Center, and Centre for Integrative Bioinformatics (AvdV), VU University, Amsterdam, the Netherlands; Department of Ricerca Traslazionale e delle Nuove Tecnologie in Medicina e Chirurgia, University of Pisa, Pisa, Italy (NF, UB, EV); Department of Neurology, Stanford University, Stanford, CA (VC); Department of Neurology, Massachusetts General Hospital and Neuroscience Program, Harvard Medical School, Boston, MA (TW); Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD (QW, J-HL, YW, GG).
Abstract
BACKGROUND: Loss of 18q22.3 is a prognostic marker in pancreatic ductal adenocarcinoma (PDAC). This study investigated genes encoded by this cytoband. METHODS: We studied mRNA/protein expression in radically resected (n = 130) and metastatic patients (n = 50). The role of CYB5A was tested in 11 PDAC cell lines and five primary cultures through retrovirus-mediated upregulation and small interfering RNA using wound-healing, invasion, annexin-V, electron microscopy, and autophagic assays, as well as autophagy genes and kinases arrays. CYB5A+ orthotopic models (n = 6 mice/group) were monitored by Firefly and Gaussia-luciferase bioluminescence, magnetic resonance imaging, and high-frequency ultrasound. Data were analyzed by t test, Fisher exact-test, log-rank test and Cox proportional hazards models. All statistical tests were two-sided. RESULTS: Both resected and metastatic patients with low mRNA or protein expression of CYB5A had statistically significantly shorter survival (eg, median = 16.7 months, 95% confidence interval [CI] = 13.5 to 19.9; vs median = 24.8 months, 95% CI = 12.8 to 36.9; P = .02, two-sided log-rank test; n = 82 radically resected PDACs), and multivariable analyses confirmed prognostic relevance. Moreover, we characterized a novel function to CYB5A, autophagy induction, concomitant with reduced proliferation and migration/invasion of PDAC cells. Network analysis of proautophagic pathways suggested CYB5A interaction with TRAF6, which was confirmed by TRAF6 downregulation after CYB5A reconstitution (-69% in SU.86.86-CYB5A+; P = .005, two-sided t test). CYB5A silencing had opposite effects, restoring TRAF6 expression and wound healing. In vivo studies showed that CYB5A induced autophagy while inhibiting tumor growth/metastasis and increasing survival (median = 57 days, 95% CI = 52 to 61; vs median = 44 days, 95% CI = 21 to 57; P = .03, two-sided log-rank test). CONCLUSIONS: These results define CYB5A as a novel prognostic factor for PDAC that exerts its tumor-suppressor function through autophagy induction and TRAF6 modulation.
BACKGROUND: Loss of 18q22.3 is a prognostic marker in pancreatic ductal adenocarcinoma (PDAC). This study investigated genes encoded by this cytoband. METHODS: We studied mRNA/protein expression in radically resected (n = 130) and metastatic patients (n = 50). The role of CYB5A was tested in 11 PDAC cell lines and five primary cultures through retrovirus-mediated upregulation and small interfering RNA using wound-healing, invasion, annexin-V, electron microscopy, and autophagic assays, as well as autophagy genes and kinases arrays. CYB5A+ orthotopic models (n = 6 mice/group) were monitored by Firefly and Gaussia-luciferase bioluminescence, magnetic resonance imaging, and high-frequency ultrasound. Data were analyzed by t test, Fisher exact-test, log-rank test and Cox proportional hazards models. All statistical tests were two-sided. RESULTS: Both resected and metastatic patients with low mRNA or protein expression of CYB5A had statistically significantly shorter survival (eg, median = 16.7 months, 95% confidence interval [CI] = 13.5 to 19.9; vs median = 24.8 months, 95% CI = 12.8 to 36.9; P = .02, two-sided log-rank test; n = 82 radically resected PDACs), and multivariable analyses confirmed prognostic relevance. Moreover, we characterized a novel function to CYB5A, autophagy induction, concomitant with reduced proliferation and migration/invasion of PDAC cells. Network analysis of proautophagic pathways suggested CYB5A interaction with TRAF6, which was confirmed by TRAF6 downregulation after CYB5A reconstitution (-69% in SU.86.86-CYB5A+; P = .005, two-sided t test). CYB5A silencing had opposite effects, restoring TRAF6 expression and wound healing. In vivo studies showed that CYB5A induced autophagy while inhibiting tumor growth/metastasis and increasing survival (median = 57 days, 95% CI = 52 to 61; vs median = 44 days, 95% CI = 21 to 57; P = .03, two-sided log-rank test). CONCLUSIONS: These results define CYB5A as a novel prognostic factor for PDAC that exerts its tumor-suppressor function through autophagy induction and TRAF6 modulation.
Authors: N Funel; E Vasile; M Del Chiaro; U Boggi; A Falcone; D Campani; A Scarpa; E Giovannetti Journal: Ann Oncol Date: 2010-12-31 Impact factor: 32.976
Authors: Romina Pardo; Andrea Lo Ré; Cendrine Archange; Alejandro Ropolo; Daniela L Papademetrio; Claudio D Gonzalez; Elida M Alvarez; Juan L Iovanna; Maria I Vaccaro Journal: Pancreatology Date: 2010-03-19 Impact factor: 3.996
Authors: Daniel T Starczynowski; William W Lockwood; Sophie Deléhouzée; Raj Chari; Joanna Wegrzyn; Megan Fuller; Ming-Sound Tsao; Stephen Lam; Adi F Gazdar; Wan L Lam; Aly Karsan Journal: J Clin Invest Date: 2011-09-12 Impact factor: 14.808
Authors: Patrick Naumann; Franco Fortunato; Hanswalter Zentgraf; Markus W Büchler; Ingrid Herr; Jens Werner Journal: Int J Oncol Date: 2011-04-29 Impact factor: 5.650
Authors: Amir Avan; Viola Caretti; Niccola Funel; Elena Galvani; Mina Maftouh; Richard J Honeywell; Tonny Lagerweij; Olaf Van Tellingen; Daniela Campani; Dieter Fuchs; Henk M Verheul; Gerrit-Jan Schuurhuis; Ugo Boggi; Godefridus J Peters; Thomas Würdinger; Elisa Giovannetti Journal: Cancer Res Date: 2013-10-01 Impact factor: 12.701
Authors: Shinichi Yachida; Siân Jones; Ivana Bozic; Tibor Antal; Rebecca Leary; Baojin Fu; Mihoko Kamiyama; Ralph H Hruban; James R Eshleman; Martin A Nowak; Victor E Velculescu; Kenneth W Kinzler; Bert Vogelstein; Christine A Iacobuzio-Donahue Journal: Nature Date: 2010-10-28 Impact factor: 49.962
Authors: Ahva Shahabi; Juan Pablo Lewinger; Jie Ren; Craig April; Andy E Sherrod; Joseph G Hacia; Siamak Daneshmand; Inderbir Gill; Jacek K Pinski; Jian-Bing Fan; Mariana C Stern Journal: Prostate Date: 2016-06-08 Impact factor: 4.012
Authors: Maria Rovithi; Amir Avan; Niccola Funel; Leticia G Leon; Valentina E Gomez; Thomas Wurdinger; Arjan W Griffioen; Henk M W Verheul; Elisa Giovannetti Journal: Sci Rep Date: 2017-03-17 Impact factor: 4.379